XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that Dr. Florian A. Sahr has joined its European operations as head of project management. A German-born and internationally trained leader in formulation, technology transfer and new-product manufacturing, Dr. Sahr has a strong track record of drug development. This includes transdermal (“TDS”) and oral dissolvable (“ODF”) delivery systems and the physical and regulatory establishment of GMP and FDA compliant pharmaceutical manufacturing facilities. Employment highlights of his work include serving as senior scientist, head of manufacturing, Gen-Plus GmbH & Co. KG, Munich, Germany, where he developed TDS and ODF drug formulations and transferred these new formulations and technologies to manufacturing systems and facilities. In addition, his work as project manager, advanced projects, tesa Labtec GmbH, Langenfeld, Germany, focused on project management and technology transfer of generic TDS formulations to the company’s manufacturing facilities. Dr. Sahr has held the regulated position of head of manufacturing according to the German Medicines Act (“AMG/AMWHV”) for the production of clinical trial materials for a number of companies.
To view the full press release, visit https://ibn.fm/zYcDp
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
